摘要
背景:Leber遗传性视神经病变是一种遗传性线粒体疾病。到目前为止还没有建立有效的治疗方法,基因治疗是目前最有希望的治疗方法。因为对于本病的自发视力恢复的可能性,我们在基因治疗前对患者进行了筛选,不包括有自发视力改善的患者,并为治疗做好了准备。基因治疗。 目的:观察Leber遗传性视神经病变在基因治疗前6个月的临床表现。 方法:对66例Leber氏遗传性视神经病变患者进行研究.患者按病程分类:少于24个月和超过24个月。THREE临床随访1年以上。我们评估了眼压、视力、视野、视网膜神经纤维层厚度、眼底照片和视觉诱发。潜在的,有可能的. 结果:82只眼视力稳定,其中双眼34只眼,1只眼14只眼;22只眼33只眼视力下降(少于24个月)。24只眼,24个月以上9只眼,12只眼中17只眼视力改善(少于24个月:4只眼;超过24个月:13只眼)。视力和视野指数发病24个月后下降,24个月后趋于稳定。 结论:大多数Leber遗传性视神经病变患者随着发病时间的延长,视力逐渐稳定,自发视力恢复的可能性较低。ASIS用于未来基因治疗效果的评价。
关键词: 基因治疗,视网膜神经纤维层厚度,视力,视觉诱发电位,视野,自发视力恢复,稳定视力。
Current Gene Therapy
Title:Clinical Observation of Patients with Leber’s Hereditary Optic Neuropathy Before Gene Therapy
Volume: 18 Issue: 6
关键词: 基因治疗,视网膜神经纤维层厚度,视力,视觉诱发电位,视野,自发视力恢复,稳定视力。
摘要: Background: Leber’s hereditary optic neuropathy is a hereditary mitochondrial disease. No effective treatment has so far been established, with gene therapy currently being the most promising. Because of the possibility of spontaneous visual acuity recovery in this disease, we screened patients before gene therapy, excluding those with spontaneous visual acuity improvement, and prepared for the subsequent gene therapy.
Objective: To clinically observe the course of Leber’s hereditary optic neuropathy for 6 months prior to gene therapy.
Methods: Sixty-six patients with Leber’s hereditary optic neuropathy were enrolled in the study. Patients were classified based on the duration of disease: less than 24 months and over 24 months. Three clinical follow-up examinations were conducted over 1 year. We assessed intraocular pressure, visual acuity, visual field, retinal nerve fiber layer thickness, fundus photographs, and visual evoked potential.
Results: Eighty-two eyes displayed stable visual acuity, including both eyes in 34 patients and one eye in 14 patients; 33 eyes of 22 patients displayed decrease in visual acuity (less than 24 months: 24 eyes; over 24 months: nine eyes); and 17 eyes of 12 patients showed improvement in visual acuity (less than 24 months: four eyes; over 24 months: 13 eyes). Visual acuity and visual field indices decreased over 24 months from disease onset and appeared stable after 24 months.
Conclusion: Most patients with Leber’s hereditary optic neuropathy gradually stabilize visual function with prolonged onset time, and the lower possibility of spontaneous vision recovery provides a basis for future evaluation of the effectiveness of gene therapy.
Export Options
About this article
Cite this article as:
Clinical Observation of Patients with Leber’s Hereditary Optic Neuropathy Before Gene Therapy, Current Gene Therapy 2018; 18 (6) . https://dx.doi.org/10.2174/1566523218666181105125245
DOI https://dx.doi.org/10.2174/1566523218666181105125245 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements